FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2403378328> ?p ?o ?g. }

• W2403378328 endingPage "83" @default.
• W2403378328 startingPage "82" @default.
• W2403378328 abstract "Drug repositioning and molecularly targeted novel drug development are two contrasting strategies in cancer research. Yet, certain combinations of the two may bring together the best of both worlds. Drug repositioning, i.e. the use of a drug for treating diseases other than the drug-specified, is a strategy to advance patient care more quickly and efficiently. The idea was promoted in 2012 through the Discovering New Therapeutic Uses for Existing Molecules program, initiated by NIH. Several drugs used for other purposes have proved to be effective anti-cancer agents, including thalidomide, aspirin, and celecoxib. In contrast, novel drug development is a lengthy process. Molecularly tailored drugs fail for various reasons including inadequate bioavailability and adverse side effects, and are often very expensive. Despite drawbacks to targeted drug development, there are also successes in this area of research. Cancer therapeutics designed to inhibit kinases involved in cell growth and survival pathways are potent and selective in the short term. By directly blocking cell signaling, often at the source of over-activation, these drugs kill cancer cells. One example of success in targeted therapy is the development of BRAFV600E inhibitors, vemurafenib and dabrafenib, and their ability to prolong progression-free survival time in melanoma patients. However, a major problem with monotherapy is the inevitable development of resistance. Even with combination treatment using specific inhibitors, such as BRAFV600E and MEK inhibitors in melanoma, improvement in patient outcome is limited [1,2] and resistance emerges. There is increasing interest in combining targeted inhibitors with common metabolic regulators to hinder resistance. This unique combination reaps both the intrinsic benefits of repurposing drugs and the selectivity of targeted therapy. The major biguanides, metformin and phenformin, have known pharmacokinetics, high safety profiles, and are relatively inexpensive. Metformin in particular is widely used for treatment of patients with type 2 diabetes. Although there is evidence in literature for both pro-cancer and anti-cancer effects of metformin on cancer cells, a clear association between metformin therapy and reduced risk of cancer in diabetic patients exists. Recent studies point out direct cellular benefits of combining biguanides with current targeted therapy." @default.
• W2403378328 created "2016-06-24" @default.
• W2403378328 creator A5006700242 @default.
• W2403378328 creator A5006905292 @default.
• W2403378328 creator A5086304089 @default.
• W2403378328 date "2015-04-16" @default.
• W2403378328 modified "2023-10-06" @default.
• W2403378328 title "Biguanides and targeted anti-cancer treatments" @default.
• W2403378328 cites W1758894002 @default.
• W2403378328 cites W1921975008 @default.
• W2403378328 cites W2031134972 @default.
• W2403378328 cites W2096387850 @default.
• W2403378328 cites W2101774229 @default.
• W2403378328 cites W2121545342 @default.
• W2403378328 cites W2912180662 @default.
• W2403378328 doi "https://doi.org/10.18632/genesandcancer.59" @default.
• W2403378328 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4426946" @default.
• W2403378328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26000092" @default.
• W2403378328 hasPublicationYear "2015" @default.
• W2403378328 type Work @default.
• W2403378328 sameAs 2403378328 @default.
• W2403378328 citedByCount "5" @default.
• W2403378328 countsByYear W24033783282016 @default.
• W2403378328 countsByYear W24033783282018 @default.
• W2403378328 countsByYear W24033783282021 @default.
• W2403378328 countsByYear W24033783282023 @default.
• W2403378328 crossrefType "journal-article" @default.
• W2403378328 hasAuthorship W2403378328A5006700242 @default.
• W2403378328 hasAuthorship W2403378328A5006905292 @default.
• W2403378328 hasAuthorship W2403378328A5086304089 @default.
• W2403378328 hasBestOaLocation W24033783281 @default.
• W2403378328 hasConcept C121608353 @default.
• W2403378328 hasConcept C126322002 @default.
• W2403378328 hasConcept C177713679 @default.
• W2403378328 hasConcept C60644358 @default.
• W2403378328 hasConcept C71924100 @default.
• W2403378328 hasConcept C86803240 @default.
• W2403378328 hasConceptScore W2403378328C121608353 @default.
• W2403378328 hasConceptScore W2403378328C126322002 @default.
• W2403378328 hasConceptScore W2403378328C177713679 @default.
• W2403378328 hasConceptScore W2403378328C60644358 @default.
• W2403378328 hasConceptScore W2403378328C71924100 @default.
• W2403378328 hasConceptScore W2403378328C86803240 @default.
• W2403378328 hasIssue "3-4" @default.
• W2403378328 hasLocation W24033783281 @default.
• W2403378328 hasLocation W24033783282 @default.
• W2403378328 hasLocation W24033783283 @default.
• W2403378328 hasLocation W24033783284 @default.
• W2403378328 hasOpenAccess W2403378328 @default.
• W2403378328 hasPrimaryLocation W24033783281 @default.
• W2403378328 hasRelatedWork W2125404273 @default.
• W2403378328 hasRelatedWork W2151952923 @default.
• W2403378328 hasRelatedWork W2333838168 @default.
• W2403378328 hasRelatedWork W2537513708 @default.
• W2403378328 hasRelatedWork W2562836009 @default.
• W2403378328 hasRelatedWork W2567435681 @default.
• W2403378328 hasRelatedWork W3087525504 @default.
• W2403378328 hasRelatedWork W3171532677 @default.
• W2403378328 hasRelatedWork W4307122605 @default.
• W2403378328 hasRelatedWork W4321459821 @default.
• W2403378328 hasVolume "6" @default.
• W2403378328 isParatext "false" @default.
• W2403378328 isRetracted "false" @default.
• W2403378328 magId "2403378328" @default.
• W2403378328 workType "article" @default.